Literature DB >> 24702226

Clinical features, presenting symptoms, and surgical results of congenital cholesteatoma based on Potsic's staging system.

Taro Takagi1, Kiyofumi Gyo, Nobuhiro Hakuba, Jun Hyodo, Naohito Hato.   

Abstract

CONCLUSIONS: Potsic's staging system is a clinically useful procedure for evaluating the extent of congenital cholesteatoma (CC).
OBJECTIVES: We investigated the clinical features, presenting symptoms, and surgical results of CC according to Potsic's staging system.
METHODS: A total of 71 patients who had undergone surgery at our hospital were retrospectively analyzed for presenting symptoms, the location of cholesteatoma, and surgical results according to Potsic's staging system.
RESULTS: Of the 71 patients, 21 were classified as Potsic stage I, 9 as stage II, 31 as stage III, and 10 as stage IV. More than half of the patients with early-stage CC (stages I and II) were diagnosed asymptomatically by a chance visit to a clinic or on ear screening. Others were diagnosed following a complaint of hearing loss, acute otitis media, or otitis media with effusion. The location of CC varied somewhat by stage. In stage I CC, the most frequent location was behind the anterior-superior quadrant of the tympanic membrane; however, in stage III CC, it was behind the posterior-superior quadrant. All patients were treated surgically. Recurrence was detected in 2 of the 71 patients (2.8%); both had stage II CC. Recurrent lesions were removed during revision surgery.

Entities:  

Mesh:

Year:  2014        PMID: 24702226     DOI: 10.3109/00016489.2013.875218

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  2 in total

1.  Congenital cholesteatoma: Different clinical presentation in two cases.

Authors:  S Abdul Jalil; M K Md Daud
Journal:  Malays Fam Physician       Date:  2016-08-31

2.  Clinical Characteristics and Treatment Outcomes of Congenital Cholesteatoma.

Authors:  In Sik Song; Won Gue Han; Kang Hyeon Lim; Kuk Jin Nam; Myung Hoon Yoo; Yoon Chan Rah; June Choi
Journal:  J Int Adv Otol       Date:  2019-12       Impact factor: 1.017

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.